Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 22, 2026

Is It Time To Reassess McDonald's (MCD) After Recent Share Price Weakness?

View original at finance.yahoo.com
Is It Time To Reassess McDonald's (MCD) After Recent Share Price Weakness? Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • McDonald's has 49 high-quality undervalued stocks available as alternatives identified by Simply Wall St

    60% confidence

  • McDonald's discounted free cash flows through 2035 range from approximately $7.1 billion to $7.7 billion in present value terms across the projection years

    60% confidence

  • Analyst estimates and Simply Wall St extrapolations project McDonald's free cash flow at approximately $9.7 billion in 2028

    60% confidence

  • McDonald's is estimated to be approximately 12.3% above its DCF intrinsic value, indicating it is overvalued on this model

    60% confidence

  • McDonald's scores 2 out of 6 on Simply Wall St's valuation checks

    60% confidence

  • McDonald's latest twelve-month free cash flow is approximately $7.5 billion

    60% confidence

  • Recent news around McDonald's has focused on its position as a global consumer brand, ongoing store investments, and stock performance relative to consumer services peers

    60% confidence

  • McDonald's DCF intrinsic value is estimated at approximately $251.31 per share using a 2-Stage Free Cash Flow to Equity model

    60% confidence

Data points we hold from this source

McDonald's Corporation · stock price282 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Is It Time To Reassess McDonald's (MCD) After Recent Share Price Weakness? — Source | Via News | ViaNews EU